Results 21 to 30 of about 2,385 (197)

Cangrelor

Journal of the American College of Cardiology, 2017
Antiplatelet therapy with a P2Y12 inhibitor is a key component of treatment for patients with acute coronary syndromes undergoing percutaneous coronary intervention. Before the development of cangrelor (Kengreal, The Medicines Company, Parsippany, NJ), only oral P2Y12 inhibitors were available.
Alexandra M, Sible, James J, Nawarskas
  +6 more sources

Safety of Low Dose Intravenous Cangrelor in Acute Ischemic Stroke: A Case Series

Frontiers in Neurology, 2021
Background: Neurointerventional procedures in acute ischemic stroke often require immediate antiplatelet therapy in the cases of acute stenting and occasionally re-occluding vessels.
Hisham Salahuddin, Hisham Salahuddin, Hisham Salahuddin, Giana Dawod, Syed F. Zaidi, Syed F. Zaidi, Julie Shawver, Richard Burgess, Mouhammad A. Jumaa, Mouhammad A. Jumaa   +9 more
doaj   +1 more source

Cangrelor [PDF]

Hospital Pharmacy, 2015
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J. Cada, Danial E. Baker, Kyle T. Ingram   +2 more
openaire   +2 more sources

Tirofiban-Associated Profound Thrombocytopenia in a Patient With Glucose-6-Phosphate Dehydrogenase Deficiency Undergoing Primary Percutaneous Coronary Intervention: A Case Report. [PDF]

Case Rep Cardiol
Background Profound thrombocytopenia after tirofiban exposure during primary percutaneous coronary intervention (PCI) is rare but clinically important. Causal attribution may be challenging when unfractionated heparin is coadministered, and the relevance of glucose‐6‐phosphate dehydrogenase (G6PD) deficiency remains uncertain.
Zhao C, Wang Y, Gao S, Meng W, Yang Y, Tan W.   +5 more
europepmc   +2 more sources

Efficacy of a Combined Antiplatelet Therapy Is Not Affected by a Simultaneous Binding of Cangrelor and PSB 0777 to Albumin

Frontiers in Pharmacology, 2021
Concurrent administration of two drugs may complicate the management of acute coronary syndromes: competitive drug displacement diminishes drug binding and alters drug pharmacodynamics.
Joanna Wzorek, Radosław Bednarek, Cezary Watala, Magdalena Boncler   +3 more
doaj   +1 more source

Cangrelor ameliorates CLP-induced pulmonary injury in sepsis by inhibiting GPR17

European Journal of Medical Research, 2021
Background Sepsis is a common complication of severe wound injury and infection, with a very high mortality rate. The P2Y12 receptor inhibitor, cangrelor, is an antagonist anti-platelet drug.
Qiancheng Luo, Rui Liu, Kaili Qu, Guorong Liu, Min Hang, Guo Chen, Lei Xu, Qinqin Jin, Dongfeng Guo, Qi Kang   +9 more
doaj   +1 more source

Abstract 1122‐000210: Cangrelor to Prevent Intraluminal Thrombosis in Endovascular Therapy for Acute Stroke: Single Center Case Series

Stroke: Vascular and Interventional Neurology, 2021
Introduction: Intraluminal thrombosis after endovascular therapy (EVT) is a peri‐procedural complication that carries a high burden of morbidity and mortality. The use of anti‐thrombotic therapies during EVT remains an evolving field.
Dan Tong Jia, Dan Tong Jia, Ramez Abdalla, Sameer Ansari   +3 more
doaj   +1 more source

Cangrelor use in routine practice: a two-center experience [PDF]

, 2021
Cangrelor is the first and only intravenous P2Y 12-inhibitor and is indicated when (timely) administration of an oral P2Y 12 inhibitor is not feasible in patients undergoing percutaneous coronary intervention (PCI). Our study evaluated the first years of
Claessen, Bimmer E.P.M., Verouden, Niels J. W., Nap, Alexander, Marcel A. M. Beijk, Henriques, José P. S., José P. S. Henriques, Beijk, Marcel A.M., van der Sangen, Niels M. R., Alexander Nap, Delewi, Ronak, Knaapen, Paul, Ho Yee Cheung, Lemkes, Jorrit S., Bimmer E. P. M. Claessen, Niels M. R. van der Sangen, Claessen, Bimmer E. P. M., Kikkert, Wouter J., Cheung, Ho Yee, van der Sangen, Niels M.R., Henriques, José P.S., M. Marije Vis, Yolande Appelman, Niels J. W. Verouden, Ronak Delewi, Jorrit S. Lemkes, Verouden, Niels J.W., Wouter J. Kikkert, Appelman, Yolande, Paul Knaapen, Beijk, Marcel A. M., Vis, M. Marije   +30 more
core   +1 more source

Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial

Thrombosis Journal, 2022
Background High on-treatment platelet reactivity (HTPR) remains a major problem in the acute management of ST-elevation myocardial infarction (STEMI), leading to higher rates of stent thrombosis and mortality. We aimed to investigate a novel, prehospital
Georg Gelbenegger, Juergen Grafeneder, Gloria M. Gager, Jolanta M. Siller-Matula, Michael Schwameis, Bernd Jilma, Christian Schoergenhofer   +6 more
doaj   +1 more source

Comparative effectiveness of Cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. registry

Scientific Reports, 2023
Cangrelor, the first intravenous P2Y12 inhibitor (P2Y12-I), has been approved on the basis of three large RCTs from the CHAMPION program which nevertheless have been criticized for the low bleeding risk of the enrolled patients, the large quote of ...
Martino Pepe, Eugenio Carulli, Claudio Larosa, Gianluigi Napoli, Palma Luisa Nestola, Maria Cristina Carella, Salvatore Giordano, Rocco Tritto, Francesco Bartolomucci, Plinio Cirillo, Giuseppe Biondi Zoccai, Arturo Giordano, Marco Matteo Ciccone   +12 more
doaj   +1 more source